{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:53:29Z","timestamp":1791921209194,"version":"4.3.4"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41380-025-03143-5","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:35:27Z","timestamp":1756208127000},"page":"635-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The NMDAR\/TRPM4 death complex is a major promoter of disease progression in the 5xFAD mouse model of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"31","author":[{"given":"Jing","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6047-4682","authenticated-orcid":false,"given":"Xiaohui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9326-2290","authenticated-orcid":false,"given":"Omar A.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-5336","authenticated-orcid":false,"given":"Anna M.","family":"Hagenston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-8723","authenticated-orcid":false,"given":"Zhe-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-4348","authenticated-orcid":false,"given":"Hilmar","family":"Bading","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"3143_CR1","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-beta pathway in Alzheimer\u2019s disease. Mol Psychiatry. 2021;26:5481\u2013503.","journal-title":"Mol Psychiatry"},{"key":"3143_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/brain\/awad005","volume":"146","author":"R Perneczky","year":"2023","unstructured":"Perneczky R, Jessen F, Grimmer T, Levin J, Floel A, Peters O, et al. Anti-amyloid antibody therapies in Alzheimer\u2019s disease. Brain. 2023;146:842\u20139.","journal-title":"Brain"},{"key":"3143_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","volume":"30","author":"LK Huang","year":"2023","unstructured":"Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. J Biomed Sci. 2023;30:83.","journal-title":"J Biomed Sci"},{"key":"3143_CR4","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Sabbagh M, Cohen S. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:1631\u20132.","journal-title":"N Engl J Med"},{"key":"3143_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"3143_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3390\/ph16081085","volume":"16","author":"J Yan","year":"2023","unstructured":"Yan J, Bading H. The disruption of NMDAR\/TRPM4 death signaling with twinf interface inhibitors: a new pharmacological principle for neuroprotection. Pharmaceuticals. 2023;16:1085.","journal-title":"Pharmaceuticals"},{"key":"3143_CR7","doi-asserted-by":"publisher","first-page":"eaay3302","DOI":"10.1126\/science.aay3302","volume":"370","author":"J Yan","year":"2020","unstructured":"Yan J, Bengtson CP, Buchthal B, Hagenston AM, Bading H. Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants. Science. 2020;370:eaay3302.","journal-title":"Science"},{"key":"3143_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0301-0082(00)00067-8","volume":"65","author":"NC Danbolt","year":"2001","unstructured":"Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65:1\u2013105.","journal-title":"Prog Neurobiol"},{"key":"3143_CR9","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1126\/science.276.5319.1699","volume":"276","author":"K Tanaka","year":"1997","unstructured":"Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 1997;276:1699\u2013702.","journal-title":"Science"},{"key":"3143_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ana.410400512","volume":"40","author":"E Masliah","year":"1996","unstructured":"Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 1996;40:759\u201366.","journal-title":"Ann Neurol"},{"key":"3143_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1046\/j.1471-4159.2001.00451.x","volume":"78","author":"CM Lauderback","year":"2001","unstructured":"Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer\u2019s disease brain: the role of Abeta1-42. J Neurochem. 2001;78:413\u20136.","journal-title":"J Neurochem"},{"key":"3143_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-2007-11113","volume":"11","author":"CP Jacob","year":"2007","unstructured":"Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer\u2019s disease. J Alzheimers Dis. 2007;11:97\u2013116.","journal-title":"J Alzheimers Dis"},{"key":"3143_CR13","doi-asserted-by":"publisher","first-page":"553.e551","DOI":"10.1016\/j.neurobiolaging.2010.03.008","volume":"32","author":"HA Scott","year":"2011","unstructured":"Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR. Glutamate transporter variants reduce glutamate uptake in Alzheimer\u2019s disease. Neurobiol Aging. 2011;32:553.e551\u2013511.","journal-title":"Neurobiol Aging"},{"key":"3143_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/NEN.0b013e3181e24adb","volume":"69","author":"RL Woltjer","year":"2010","unstructured":"Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, Montine TJ, et al. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol. 2010;69:667\u201376.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3143_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/00005072-199708000-00008","volume":"56","author":"S Li","year":"1997","unstructured":"Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol. 1997;56:901\u201311.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3143_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s12276-023-01148-0","volume":"56","author":"J Kim","year":"2024","unstructured":"Kim J, Yoo ID, Lim J, Moon JS. Pathological phenotypes of astrocytes in Alzheimer\u2019s disease. Exp Mol Med. 2024;56:95\u201399.","journal-title":"Exp Mol Med"},{"key":"3143_CR17","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1523\/JNEUROSCI.5274-12.2013","volume":"33","author":"A Scimemi","year":"2013","unstructured":"Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG. Amyloid-beta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci. 2013;33:5312\u20138.","journal-title":"J Neurosci"},{"key":"3143_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neuron.2009.05.012","volume":"62","author":"S Li","year":"2009","unstructured":"Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788\u2013801.","journal-title":"Neuron"},{"key":"3143_CR19","doi-asserted-by":"publisher","first-page":"E2518","DOI":"10.1073\/pnas.1306832110","volume":"110","author":"M Talantova","year":"2013","unstructured":"Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, et al. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA. 2013;110:E2518\u20132527.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3143_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1084\/jem.20161673","volume":"214","author":"H Bading","year":"2017","unstructured":"Bading H. Therapeutic targeting of the pathological triad of extrasynaptic NMDA receptor signaling in neurodegenerations. J Exp Med. 2017;214:569\u201378.","journal-title":"J Exp Med"},{"key":"3143_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nn835","volume":"5","author":"GE Hardingham","year":"2002","unstructured":"Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405\u201314.","journal-title":"Nat Neurosci"},{"key":"3143_CR22","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3143_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2003;348:1333\u201341.","journal-title":"N Engl J Med"},{"key":"3143_CR24","doi-asserted-by":"publisher","first-page":"e0123289","DOI":"10.1371\/journal.pone.0123289","volume":"10","author":"S Matsunaga","year":"2015","unstructured":"Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer\u2019s disease: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0123289.","journal-title":"PLoS ONE"},{"key":"3143_CR25","doi-asserted-by":"publisher","first-page":"11246","DOI":"10.1523\/JNEUROSCI.2488-10.2010","volume":"30","author":"P Xia","year":"2010","unstructured":"Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30:11246\u201350.","journal-title":"J Neurosci"},{"key":"3143_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neuropharm.2013.04.014","volume":"74","author":"RG Morris","year":"2013","unstructured":"Morris RG. NMDA receptors and memory encoding. Neuropharmacology. 2013;74:32\u201340.","journal-title":"Neuropharmacology"},{"key":"3143_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrn2911","volume":"11","author":"GE Hardingham","year":"2010","unstructured":"Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682\u201396.","journal-title":"Nat Rev Neurosci"},{"key":"3143_CR28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/0165-0173(94)00014-G","volume":"20","author":"G Ellison","year":"1995","unstructured":"Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev. 1995;20:250\u201367.","journal-title":"Brain Res Brain Res Rev"},{"key":"3143_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","volume":"20","author":"JW Newcomer","year":"1999","unstructured":"Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106\u201318.","journal-title":"Neuropsychopharmacology"},{"key":"3143_CR30","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0022-3565(24)35047-5","volume":"290","author":"P Andine","year":"1999","unstructured":"Andine P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E, et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther. 1999;290:1393\u2013408.","journal-title":"J Pharmacol Exp Ther"},{"key":"3143_CR31","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1523\/JNEUROSCI.4883-05.2006","volume":"26","author":"C Creeley","year":"2006","unstructured":"Creeley C, Wozniak DF, Labruyere J, Taylor GT, Olney JW. Low doses of memantine disrupt memory in adult rats. J Neurosci. 2006;26:3923\u201332.","journal-title":"J Neurosci"},{"key":"3143_CR32","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1126\/science.1835799","volume":"254","author":"JW Olney","year":"1991","unstructured":"Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515\u20138.","journal-title":"Science"},{"key":"3143_CR33","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1126\/science.2660263","volume":"244","author":"JW Olney","year":"1989","unstructured":"Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360\u20132.","journal-title":"Science"},{"key":"3143_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109737","volume":"244","author":"P Karimi Tari","year":"2024","unstructured":"Karimi Tari P, Parsons CG, Collingridge GL, Rammes G. Memantine: updating a rare success story in pro-cognitive therapeutics. Neuropharmacology. 2024;244:109737.","journal-title":"Neuropharmacology"},{"key":"3143_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101413","volume":"5","author":"J Yan","year":"2024","unstructured":"Yan J, Wang YM, Hellwig A, Bading H. TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS. Cell Rep Med. 2024;5:101413.","journal-title":"Cell Rep Med"},{"key":"3143_CR36","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1021\/acs.jmedchem.4c02772","volume":"68","author":"M Sun","year":"2025","unstructured":"Sun M, Wang L, Cao Q, Wang X, Zhang Y, Guo M, et al. Discovery of HZS60 as a novel brain penetrant NMDAR\/TRPM4 interaction interface inhibitor with improved activity and pharmacokinetic properties for the treatment of cerebral ischemia. J Med Chem. 2025;68:2008\u201343.","journal-title":"J Med Chem"},{"key":"3143_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s40478-024-01858-0","volume":"12","author":"YM Wang","year":"2024","unstructured":"Wang YM, Yan J, Williams SK, Fairless R, Bading H. TwinF interface inhibitor FP802 prevents retinal ganglion cell loss in a mouse model of amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2024;12:149.","journal-title":"Acta Neuropathol Commun"},{"key":"3143_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/cells14030195","volume":"14","author":"OA Ramirez","year":"2025","unstructured":"Ramirez OA, Hellwig A, Zhang Z, Bading H. Pharmacological targeting of the NMDAR\/TRPM4 death signaling complex with a twinf interface inhibitor prevents excitotoxicity-associated dendritic blebbing and organelle damage. Cells. 2025;14:195.","journal-title":"Cells"},{"key":"3143_CR39","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1523\/JNEUROSCI.5048-11.2012","volume":"32","author":"H Yu","year":"2012","unstructured":"Yu H, Wang DD, Wang Y, Liu T, Lee FS, Chen ZY. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J Neurosci. 2012;32:4092\u2013101.","journal-title":"J Neurosci"},{"key":"3143_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115146","volume":"44","author":"SW Teng","year":"2025","unstructured":"Teng SW, Wang XR, Yao ZX, He T, Gao MY, Che YY, et al. Coordinated excitatory and inhibitory circuits governing unpredictable threat-induced anxiety. Cell Rep. 2025;44:115146.","journal-title":"Cell Rep"},{"key":"3143_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.neurobiolaging.2014.08.005","volume":"36","author":"J Yan","year":"2015","unstructured":"Yan J, Liu XH, Han MZ, Wang YM, Sun XL, Yu N, et al. Blockage of GSK3beta-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer\u2019s disease. Neurobiol Aging. 2015;36:211\u201327.","journal-title":"Neurobiol Aging"},{"key":"3143_CR42","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nn.3151","volume":"15","author":"AM Oliveira","year":"2012","unstructured":"Oliveira AM, Hemstedt TJ, Bading H. Rescue of aging-associated decline in Dnmt3a2 expression restores cognitive abilities. Nat Neurosci. 2012;15:1111\u20133.","journal-title":"Nat Neurosci"},{"key":"3143_CR43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1126\/science.1129663","volume":"314","author":"ZY Chen","year":"2006","unstructured":"Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314:140\u20133.","journal-title":"Science"},{"key":"3143_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41592-021-01105-7","volume":"18","author":"C Arshadi","year":"2021","unstructured":"Arshadi C, Gunther U, Eddison M, Harrington KIS, Ferreira TA. SNT: a unifying toolbox for quantification of neuronal anatomy. Nat Methods. 2021;18:374\u20137.","journal-title":"Nat Methods"},{"key":"3143_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf0284","volume":"9","author":"SW Teng","year":"2023","unstructured":"Teng SW, Wang XR, Du BW, Chen XL, Fu GZ, Liu YF, et al. Altered fear engram encoding underlying conditioned versus unconditioned stimulus-initiated memory updating. Sci Adv. 2023;9:eadf0284.","journal-title":"Sci Adv"},{"key":"3143_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-021-01054-y","volume":"8","author":"S Forner","year":"2021","unstructured":"Forner S, Kawauchi S, Balderrama-Gutierrez G, Kramar EA, Matheos DP, Phan J, et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer\u2019s disease. Sci Data. 2021;8:270.","journal-title":"Sci Data"},{"key":"3143_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbb.2016.03.002","volume":"144","author":"L Devi","year":"2016","unstructured":"Devi L, Ohno M. Cognitive benefits of memantine in Alzheimer\u2019s 5XFAD model mice decline during advanced disease stages. Pharmacol Biochem Behav. 2016;144:60\u201366.","journal-title":"Pharmacol Biochem Behav"},{"key":"3143_CR48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/alz.12683","volume":"19","author":"T Ashleigh","year":"2023","unstructured":"Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer\u2019s disease pathogenesis. Alzheimers Dement. 2023;19:333\u201342.","journal-title":"Alzheimers Dement"},{"key":"3143_CR49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bbadis.2009.10.006","volume":"1802","author":"PI Moreira","year":"2010","unstructured":"Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer\u2019s disease pathophysiology. Biochim Biophys Acta. 2010;1802:2\u201310.","journal-title":"Biochim Biophys Acta"},{"key":"3143_CR50","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1523\/JNEUROSCI.21-09-03017.2001","volume":"21","author":"K Hirai","year":"2001","unstructured":"Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer\u2019s disease. J Neurosci. 2001;21:3017\u201323.","journal-title":"J Neurosci"},{"key":"3143_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk1051","volume":"14","author":"AV Venkataraman","year":"2022","unstructured":"Venkataraman AV, Mansur A, Rizzo G, Bishop C, Lewis Y, Kocagoncu E, et al. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer\u2019s disease. Sci Transl Med. 2022;14:eabk1051.","journal-title":"Sci Transl Med"},{"key":"3143_CR52","doi-asserted-by":"crossref","unstructured":"Keskinoz EN, Celik M, Toklucu ES, Birisik K, Erisir A, Oz-Arslan D. Mitochondrial alterations in Alzheimer\u2019s disease: insight from the 5xFAD mouse model. Mol Neurobiol. 2024.","DOI":"10.1007\/s12035-024-04632-4"},{"key":"3143_CR53","doi-asserted-by":"crossref","unstructured":"Eustaquio T, Wang C, Dugard CK, George NI, Liu F, Slikker W, Jr et al. Electron microscopy techniques employed to explore mitochondrial defects in the developing rat brain following ketamine treatment. Exp Cell Res 2018; 373: 164\u201370.","DOI":"10.1016\/j.yexcr.2018.10.009"},{"key":"3143_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances. Mol Neurodegener. 2020;15:30.","journal-title":"Mol Neurodegener"},{"key":"3143_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102713","volume":"107","author":"MCB D\u2019Alessandro","year":"2025","unstructured":"D\u2019Alessandro MCB, Kanaan S, Geller M, Pratico D, Daher JPL. Mitochondrial dysfunction in Alzheimer\u2019s disease. Ageing Res Rev. 2025;107:102713.","journal-title":"Ageing Res Rev"},{"key":"3143_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02276-y","volume":"18","author":"G Ruiz-Perez","year":"2021","unstructured":"Ruiz-Perez G, Ruiz de Martin Esteban S, Marques S, Aparicio N, Grande MT, Benito-Cuesta I, et al. Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer\u2019s disease. J Neuroinflammation. 2021;18:223.","journal-title":"J Neuroinflammation"},{"key":"3143_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.791666","volume":"13","author":"E Rodriguez-Urgelles","year":"2022","unstructured":"Rodriguez-Urgelles E, Sancho-Balsells A, Chen W, Lopez-Molina L, Ballasch I, Del Castillo I, et al. Meridianins rescue cognitive deficits, spine density and neuroinflammation in the 5xFAD model of Alzheimer\u2019s disease. Front Pharmacol. 2022;13:791666.","journal-title":"Front Pharmacol"},{"key":"3143_CR58","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ana.25049","volume":"82","author":"BD Boros","year":"2017","unstructured":"Boros BD, Greathouse KM, Gentry EG, Curtis KA, Birchall EL, Gearing M, et al. Dendritic spines provide cognitive resilience against Alzheimer\u2019s disease. Ann Neurol. 2017;82:602\u201314.","journal-title":"Ann Neurol"},{"key":"3143_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-015-1449-5","volume":"130","author":"MM Dorostkar","year":"2015","unstructured":"Dorostkar MM, Zou C, Blazquez-Llorca L, Herms J. Analyzing dendritic spine pathology in Alzheimer\u2019s disease: problems and opportunities. Acta Neuropathol. 2015;130:1\u201319.","journal-title":"Acta Neuropathol"},{"key":"3143_CR60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.neuron.2011.04.022","volume":"71","author":"D Mauceri","year":"2011","unstructured":"Mauceri D, Freitag HE, Oliveira AM, Bengtson CP, Bading H. Nuclear calcium-VEGFD signaling controls maintenance of dendrite arborization necessary for memory formation. Neuron. 2011;71:117\u201330.","journal-title":"Neuron"},{"key":"3143_CR61","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.celrep.2019.04.097","volume":"27","author":"AD Bird","year":"2019","unstructured":"Bird AD, Cuntz H. Dissecting sholl analysis into its functional components. Cell Rep. 2019;27:3081\u201396.e3085.","journal-title":"Cell Rep"},{"key":"3143_CR62","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8178","volume":"8","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xiao Z, He Z, Chen J, Wang X, Jiang L. Dendritic complexity change in the triple transgenic mouse model of Alzheimer\u2019s disease. PeerJ. 2020;8:e8178.","journal-title":"PeerJ"},{"key":"3143_CR63","doi-asserted-by":"publisher","first-page":"e59613","DOI":"10.7554\/eLife.59613","volume":"10","author":"T Miyazaki","year":"2021","unstructured":"Miyazaki T, Morimoto-Tomita M, Berthoux C, Konno K, Noam Y, Yamasaki T, et al. Excitatory and inhibitory receptors utilize distinct post- and trans-synaptic mechanisms in vivo. Elife. 2021;10:e59613.","journal-title":"Elife"},{"key":"3143_CR64","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1523\/JNEUROSCI.0161-16.2016","volume":"36","author":"R Ichikawa","year":"2016","unstructured":"Ichikawa R, Sakimura K, Watanabe M. GluD2 endows parallel fiber-purkinje cell synapses with a high regenerative capacity. J Neurosci. 2016;36:4846\u201358.","journal-title":"J Neurosci"},{"key":"3143_CR65","doi-asserted-by":"publisher","first-page":"12129","DOI":"10.1523\/JNEUROSCI.1849-16.2016","volume":"36","author":"S Ha","year":"2016","unstructured":"Ha S, Lee D, Cho YS, Chung C, Yoo YE, Kim J, et al. Cerebellar shank2 regulates excitatory synapse density, motor coordination, and specific repetitive and anxiety-like behaviors. J Neurosci. 2016;36:12129\u201343.","journal-title":"J Neurosci"},{"key":"3143_CR66","doi-asserted-by":"publisher","first-page":"e57013","DOI":"10.7554\/eLife.57013","volume":"9","author":"M Montero-Crespo","year":"2020","unstructured":"Montero-Crespo M, Dominguez-Alvaro M, Rondon-Carrillo P, Alonso-Nanclares L, DeFelipe J, Blazquez-Llorca L. Three-dimensional synaptic organization of the human hippocampal CA1 field. Elife. 2020;9:e57013.","journal-title":"Elife"},{"key":"3143_CR67","doi-asserted-by":"publisher","first-page":"a005587","DOI":"10.1101\/cshperspect.a005587","volume":"4","author":"KM Harris","year":"2012","unstructured":"Harris KM, Weinberg RJ. Ultrastructure of synapses in the mammalian brain. Cold Spring Harb Perspect Biol. 2012;4:a005587.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3143_CR68","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1038\/s41380-020-0659-y","volume":"26","author":"S Cursano","year":"2021","unstructured":"Cursano S, Battaglia CR, Urrutia-Ruiz C, Grabrucker S, Schon M, Bockmann J, et al. A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome. Mol Psychiatry. 2021;26:3778\u201394.","journal-title":"Mol Psychiatry"},{"key":"3143_CR69","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012632","volume":"13","author":"M Bae","year":"2021","unstructured":"Bae M, Roh JD, Kim Y, Kim SS, Han HM, Yang E, et al. SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function. EMBO Mol Med. 2021;13:e12632.","journal-title":"EMBO Mol Med"},{"key":"3143_CR70","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","volume":"65","author":"AJ Milnerwood","year":"2010","unstructured":"Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington\u2019s disease mice. Neuron. 2010;65:178\u201390.","journal-title":"Neuron"},{"key":"3143_CR71","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/j.1460-9568.2005.04431.x","volume":"22","author":"R Wang","year":"2005","unstructured":"Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci. 2005;22:2376\u201380.","journal-title":"Eur J Neurosci"},{"key":"3143_CR72","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/neu.480230915","volume":"23","author":"DW Choi","year":"1992","unstructured":"Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23:1261\u201376.","journal-title":"J Neurobiol"},{"key":"3143_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1523\/JNEUROSCI.07-02-00369.1987","volume":"7","author":"DW Choi","year":"1987","unstructured":"Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci. 1987;7:369\u201379.","journal-title":"J Neurosci"},{"key":"3143_CR74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuropharm.2013.03.030","volume":"74","author":"Q Zhou","year":"2013","unstructured":"Zhou Q, Sheng M. NMDA receptors in nervous system diseases. Neuropharmacology. 2013;74:69\u201375.","journal-title":"Neuropharmacology"},{"key":"3143_CR75","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S1474-4422(08)70165-0","volume":"7","author":"LV Kalia","year":"2008","unstructured":"Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7:742\u201355.","journal-title":"Lancet Neurol"},{"key":"3143_CR76","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn3504","volume":"14","author":"P Paoletti","year":"2013","unstructured":"Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383\u2013400.","journal-title":"Nat Rev Neurosci"},{"key":"3143_CR77","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.8097060","volume":"260","author":"H Bading","year":"1993","unstructured":"Bading H, Ginty DD, Greenberg ME. Regulation of gene expression in hippocampal neurons by distinct calcium signaling pathways. Science. 1993;260:181\u20136.","journal-title":"Science"},{"key":"3143_CR78","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.neuron.2007.01.025","volume":"53","author":"SJ Zhang","year":"2007","unstructured":"Zhang SJ, Steijaert MN, Lau D, Schutz G, Delucinge-Vivier C, Descombes P, et al. Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron. 2007;53:549\u201362.","journal-title":"Neuron"},{"key":"3143_CR79","doi-asserted-by":"publisher","first-page":"e1000604","DOI":"10.1371\/journal.pgen.1000604","volume":"5","author":"SJ Zhang","year":"2009","unstructured":"Zhang SJ, Zou M, Lu L, Lau D, Ditzel DA, Delucinge-Vivier C, et al. Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activity. PLoS Genet. 2009;5:e1000604.","journal-title":"PLoS Genet"},{"key":"3143_CR80","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrn3531","volume":"14","author":"H Bading","year":"2013","unstructured":"Bading H. Nuclear calcium signalling in the regulation of brain function. Nat Rev Neurosci. 2013;14:593\u2013608.","journal-title":"Nat Rev Neurosci"},{"key":"3143_CR81","doi-asserted-by":"publisher","first-page":"a005744","DOI":"10.1101\/cshperspect.a005744","volume":"3","author":"AE West","year":"2011","unstructured":"West AE, Greenberg ME. Neuronal activity-regulated gene transcription in synapse development and cognitive function. Cold Spring Harb Perspect Biol. 2011;3:a005744.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3143_CR82","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(02)00164-3","volume":"1","author":"C Ikonomidou","year":"2002","unstructured":"Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002;1:383\u20136.","journal-title":"Lancet Neurol"},{"key":"3143_CR83","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1046\/j.1471-4159.1995.64052004.x","volume":"64","author":"NJ Anegawa","year":"1995","unstructured":"Anegawa NJ, Lynch DR, Verdoorn TA, Pritchett DB. Transfection of N-methyl-D-aspartate receptors in a nonneuronal cell line leads to cell death. J Neurochem. 1995;64:2004\u201312.","journal-title":"J Neurochem"},{"key":"3143_CR84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neuropharm.2007.04.015","volume":"53","author":"J von Engelhardt","year":"2007","unstructured":"von Engelhardt J, Coserea I, Pawlak V, Fuchs EC, Kohr G, Seeburg PH, et al. Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology. 2007;53:10\u201317.","journal-title":"Neuropharmacology"},{"key":"3143_CR85","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.coph.2005.12.002","volume":"6","author":"KW Muir","year":"2006","unstructured":"Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol. 2006;6:53\u201360.","journal-title":"Curr Opin Pharmacol"},{"key":"3143_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2015.01.041","volume":"1603","author":"YN Wu","year":"2015","unstructured":"Wu YN, Johnson SW. Memantine selectively blocks extrasynaptic NMDA receptors in rat substantia nigra dopamine neurons. Brain Res. 2015;1603:1\u20137.","journal-title":"Brain Res"},{"key":"3143_CR87","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.neuropharm.2006.08.007","volume":"51","author":"X Zhao","year":"2006","unstructured":"Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology. 2006;51:1181\u201391.","journal-title":"Neuropharmacology"},{"key":"3143_CR88","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.1523\/JNEUROSCI.1173-17.2017","volume":"37","author":"NG Glasgow","year":"2017","unstructured":"Glasgow NG, Povysheva NV, Azofeifa AM, Johnson JW. Memantine and ketamine differentially alter NMDA receptor desensitization. J Neurosci. 2017;37:9686\u2013704.","journal-title":"J Neurosci"},{"key":"3143_CR89","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ophtha.2018.06.017","volume":"125","author":"RN Weinreb","year":"2018","unstructured":"Weinreb RN, Liebmann JM, Cioffi GA, Goldberg I, Brandt JD, Johnson CA, et al. Oral memantine for the treatment of glaucoma: design and results of 2 randomized, placebo-controlled, phase 3 studies. Ophthalmology. 2018;125:1874\u201385.","journal-title":"Ophthalmology"},{"key":"3143_CR90","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/mus.28287","volume":"71","author":"S Bhai","year":"2025","unstructured":"Bhai S, Levine T, Moore D, Bowser R, Heim AJ, Walsh M, et al. A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis. Muscle Nerve. 2025;71:63\u201372.","journal-title":"Muscle Nerve"},{"key":"3143_CR91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bbr.2010.11.053","volume":"218","author":"K Nakaya","year":"2011","unstructured":"Nakaya K, Nakagawasai O, Arai Y, Onogi H, Sato A, Niijima F, et al. Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors. Behav Brain Res. 2011;218:165\u201373.","journal-title":"Behav Brain Res"},{"key":"3143_CR92","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/syn.20472","volume":"62","author":"P Seeman","year":"2008","unstructured":"Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008;62:149\u201353.","journal-title":"Synapse"},{"key":"3143_CR93","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/jpet.104.077172","volume":"312","author":"Y Aracava","year":"2005","unstructured":"Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005;312:1195\u2013205.","journal-title":"J Pharmacol Exp Ther"},{"key":"3143_CR94","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3940(03)00398-7","volume":"343","author":"M Peeters","year":"2003","unstructured":"Peeters M, Maloteaux JM, Hermans E. Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci Lett. 2003;343:205\u20139.","journal-title":"Neurosci Lett"},{"key":"3143_CR95","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","volume":"306","author":"G Rammes","year":"2001","unstructured":"Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001;306:81\u201384.","journal-title":"Neurosci Lett"},{"key":"3143_CR96","doi-asserted-by":"publisher","first-page":"e40326","DOI":"10.1371\/journal.pone.0040326","volume":"7","author":"RH Lee","year":"2012","unstructured":"Lee RH, Tseng TY, Wu CY, Chen PY, Chen MF, Kuo JS, et al. Memantine inhibits alpha3beta2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries. PLoS ONE. 2012;7:e40326.","journal-title":"PLoS ONE"},{"key":"3143_CR97","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1089\/ars.2017.7092","volume":"29","author":"C Depp","year":"2018","unstructured":"Depp C, Bas-Orth C, Schroeder L, Hellwig A, Bading H. Synaptic activity protects neurons against calcium-mediated oxidation and contraction of mitochondria during excitotoxicity. Antioxid Redox Signal. 2018;29:1109\u201324.","journal-title":"Antioxid Redox Signal"},{"key":"3143_CR98","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","volume":"14","author":"C Cheignon","year":"2018","unstructured":"Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease. Redox Biol. 2018;14:450\u201364.","journal-title":"Redox Biol"},{"key":"3143_CR99","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nn2071","volume":"11","author":"S Papadia","year":"2008","unstructured":"Papadia S, Soriano FX, Leveille F, Martel MA, Dakin KA, Hansen HH, et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci. 2008;11:476\u201387.","journal-title":"Nat Neurosci"},{"key":"3143_CR100","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau6328","volume":"5","author":"RY Pan","year":"2019","unstructured":"Pan RY, Ma J, Kong XX, Wang XF, Li SS, Qi XL, et al. Sodium rutin ameliorates Alzheimer\u2019s disease-like pathology by enhancing microglial amyloid-beta clearance. Sci Adv. 2019;5:eaau6328.","journal-title":"Sci Adv"},{"key":"3143_CR101","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.bbabio.2014.02.007","volume":"1837","author":"CM Pinho","year":"2014","unstructured":"Pinho CM, Teixeira PF, Glaser E. Mitochondrial import and degradation of amyloid-beta peptide. Biochim Biophys Acta. 2014;1837:1069\u201374.","journal-title":"Biochim Biophys Acta"},{"key":"3143_CR102","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199205283262204","volume":"326","author":"JD Rothstein","year":"1992","unstructured":"Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326:1464\u20138.","journal-title":"N Engl J Med"},{"key":"3143_CR103","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuint.2018.04.015","volume":"123","author":"RB Laprairie","year":"2019","unstructured":"Laprairie RB, Petr GT, Sun Y, Fischer KD, Denovan-Wright EM, Rosenberg PA. Huntington\u2019s disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1. Neurochem Int. 2019;123:85\u201394.","journal-title":"Neurochem Int"},{"key":"3143_CR104","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.baga.2012.04.029","volume":"2","author":"AM Estrada-Sanchez","year":"2012","unstructured":"Estrada-Sanchez AM, Rebec GV. Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington\u2019s disease: interactions between neurons and astrocytes. Basal Ganglia. 2012;2:57\u201366.","journal-title":"Basal Ganglia"},{"key":"3143_CR105","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.neuroscience.2008.02.004","volume":"153","author":"BR Miller","year":"2008","unstructured":"Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington\u2019s disease phenotype in the R6\/2 mouse. Neuroscience. 2008;153:329\u201337.","journal-title":"Neuroscience"},{"key":"3143_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11251","volume":"7","author":"MP Parsons","year":"2016","unstructured":"Parsons MP, Vanni MP, Woodard CL, Kang R, Murphy TH, Raymond LA. Real-time imaging of glutamate clearance reveals normal striatal uptake in Huntington disease mouse models. Nat Commun. 2016;7:11251.","journal-title":"Nat Commun"},{"key":"3143_CR107","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1523\/JNEUROSCI.1871-20.2020","volume":"41","author":"D Trudler","year":"2021","unstructured":"Trudler D, Sanz-Blasco S, Eisele YS, Ghatak S, Bodhinathan K, Akhtar MW, et al. Alpha-synuclein oligomers induce glutamate release from astrocytes and excessive extrasynaptic NMDAR activity in neurons, thus contributing to synapse loss. J Neurosci. 2021;41:2264\u201373.","journal-title":"J Neurosci"},{"key":"3143_CR108","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1089\/neu.2012.2712","volume":"30","author":"GS Goodrich","year":"2013","unstructured":"Goodrich GS, Kabakov AY, Hameed MQ, Dhamne SC, Rosenberg PA, Rotenberg A. Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat. J Neurotrauma. 2013;30:1434\u201341.","journal-title":"J Neurotrauma"},{"key":"3143_CR109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jneuroim.2019.02.002","volume":"330","author":"AS de Miranda","year":"2019","unstructured":"de Miranda AS, Ferreira RN, Vieira ELM, Abreu LKS, Brant F, Vieira LB, et al. T-lymphocytes response persists following Plasmodium berghei strain Anka infection resolution and may contribute to later experimental cerebral malaria outcomes. J Neuroimmunol. 2019;330:5\u201311.","journal-title":"J Neuroimmunol"},{"key":"3143_CR110","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1074\/jbc.RA119.011268","volume":"295","author":"SK Singh","year":"2020","unstructured":"Singh SK, Plieskatt J, Chourasia BK, Singh V, Bolscher JM, Dechering KJ, et al. The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable. J Biol Chem. 2020;295:403\u201314.","journal-title":"J Biol Chem"},{"key":"3143_CR111","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1096\/fj.03-0543com","volume":"18","author":"C Rae","year":"2004","unstructured":"Rae C, McQuillan JA, Parekh SB, Bubb WA, Weiser S, Balcar VJ, et al. Brain gene expression, metabolism, and bioenergetics: interrelationships in murine models of cerebral and noncerebral malaria. FASEB J. 2004;18:499\u2013510.","journal-title":"FASEB J"},{"key":"3143_CR112","doi-asserted-by":"publisher","first-page":"e1005643","DOI":"10.1371\/journal.ppat.1005643","volume":"12","author":"CN David","year":"2016","unstructured":"David CN, Frias ES, Szu JI, Vieira PA, Hubbard JA, Lovelace J, et al. GLT-1-dependent disruption of CNS glutamate homeostasis and neuronal function by the protozoan parasite Toxoplasma gondii. PLoS Pathog. 2016;12:e1005643.","journal-title":"PLoS Pathog"},{"key":"3143_CR113","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/mp.2016.33","volume":"22","author":"AC Pereira","year":"2017","unstructured":"Pereira AC, Gray JD, Kogan JF, Davidson RL, Rubin TG, Okamoto M, et al. Age and Alzheimer\u2019s disease gene expression profiles reversed by the glutamate modulator riluzole. Mol Psychiatry. 2017;22:296\u2013305.","journal-title":"Mol Psychiatry"},{"key":"3143_CR114","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s11481-013-9476-2","volume":"8","author":"HM Brothers","year":"2013","unstructured":"Brothers HM, Bardou I, Hopp SC, Kaercher RM, Corona AW, Fenn AM, et al. Riluzole partially rescues age-associated, but not LPS-induced, loss of glutamate transporters and spatial memory. J Neuroimmune Pharmacol. 2013;8:1098\u2013105.","journal-title":"J Neuroimmune Pharmacol"},{"key":"3143_CR115","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1474-9726.2010.00593.x","volume":"9","author":"B Potier","year":"2010","unstructured":"Potier B, Billard JM, Riviere S, Sinet PM, Denis I, Champeil-Potokar G, et al. Reduction in glutamate uptake is associated with extrasynaptic NMDA and metabotropic glutamate receptor activation at the hippocampal CA1 synapse of aged rats. Aging Cell. 2010;9:722\u201335.","journal-title":"Aging Cell"},{"key":"3143_CR116","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuron.2015.11.013","volume":"89","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron. 2016;89:37\u201353.","journal-title":"Neuron"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03143-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:02:40Z","timestamp":1768849360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03143-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3143"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03143-5","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HB and JY are named inventors of the patent application for a novel class of neuroprotectants (PCT\/EP2018\/078577); HB is founder of FundaMental Pharma GmbH, Heidelberg, Germany, which licenses FP802. HB and JY are shareholders of FundaMental Pharma GmbH. Other authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal procedures were approved by the Ethical Committee of the School of Basic Medical Sciences, Shandong University (Approval Number: ECSBMSSDU2021-2-111) or by the Regierungspr\u00e4sidium Karlsruhe (Approval Number: 35-9185.81\/G-167\/19), and were performed in strict accordance with the committees\u2019 relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}